Global FTase (Farnesyltransferase) Inhibitor Pipeline Insight Report 2021: A Heterodimeric Zinc Enzyme that Belongs to the Transferases Family - ResearchAndMarkets.com

DUBLIN--()--The "FTase (Farnesyltransferase) Inhibitor - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

This "FTase (Farnesyltransferase) inhibitor - Pipeline Insight, 2021" report provides comprehensive insights about 2+ companies and 2+ pipeline drugs in FTase inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

FTASE inhibitor Understanding

FTase inhibitor: Overview

Farnesyltransferase (FTase) is a heterodimeric zinc enzyme that belongs to the transferases family. It catalyzes the synthesis of geranylgeranyl diphosphate from Trans, trans-farnesyl diphosphate and isopentenyl diphosphate. Protein farnesyltransferase (FTase) is a two-subunit enzyme that is comprised by a 48 kDa-subunit and a 46 kDa-subunit.

FTase catalyzes the post-translational addition of a hydrophobic isoprenoid farnesyl moiety from farnesyl diphosphate (FPP), to a cysteine residue of a protein substrate containing a typical CAAX motif at the carboxyl terminus.

FTase Inhibitors - Farnesyltransferase inhibitors hold considerable promise as anticancer drugs in the clinical studies. Several studies evaluated including the identification of natural products such as the chaetomellic and zaragozic acids that mimic farnesylpyrophosphate, bisubstrate transition state analogs combining elements of the farnesyl and tetrapeptide substrates and peptidomimetics that reproduce features of the carboxyl terminal tetrapeptide CA1A2X sequence. Several farnesyl transferase inhibitors are in clinical development for the treatment of solid tumors.

FTase inhibitor Emerging Drugs Chapters

This segment of the FTase inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

FTase inhibitor Emerging Drugs

Tipifarnib: Kura Oncology

Tipifarnib is an oral investigational farnesyl transferase inhibitor. It is a nonpeptidomimetic quinolinone with potential antineoplastic activity. Tipifarnib binds to and inhibits the enzyme farnesyl protein transferase. By inhibiting the farnesylation of proteins, the molecule prevents the activation of Ras oncogenes, inhibits cell growth, induces apoptosis, and inhibits angiogenesis.

Lonafarnib: Eiger Biopharmaceuticals

Lonafarnib (also known as SCH66336) is a tricyclic nonpeptidic farnesyl transferase inhibitor that competes with protein substrates for binding to farnesyl transferase. It blocks the post-translational farnesylation of prelamin A and other proteins that are targets for farnesylation. Farnesylation is essential for the function of both mutant and non-mutant lamin-A proteins, including progerin. Merck originally developed Lonafarnib and subsequently licensed it to Eiger Biopharmaceuticals.

FTase inhibitor: Therapeutic Assessment

This segment of the report provides insights about the different FTase inhibitor drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on FTase inhibitor

There are approx. 2+ key companies which are developing the FTase inhibitor. The companies which have their FTase inhibitor drug candidates in the most advanced stage, i.e. Phase III include, Eiger Biopharmaceuticals.

Phases

This report covers around 2+ products under different phases of clinical development like

  • Late-stage products (Phase III and
  • Mid-stage products (Phase II and
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

FTase inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:

  • Infusion
  • Intradermal
  • Intramuscular
  • Intranasal
  • Intravaginal
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical.
  • Molecule Type

Products have been categorized under various Molecule types such as:

  • Vaccines
  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Product Type

The drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

FTase inhibitor: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses FTase inhibitor therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging FTase inhibitor drugs.

Report Highlights

  • The companies and academics are working to assess challenges and seek opportunities that could influence FTase inhibitor R&D. The therapies under development are focused on novel approaches for FTase inhibitor.

FTase inhibitor Report Insights

  • FTASE inhibitor Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

FTase inhibitor Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions Answered

Current Scenario and Emerging Therapies:

  • How many companies are developing FTase inhibitor drugs?
  • How many FTase inhibitor drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for FTase inhibitor?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the FTase inhibitor therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for FTase inhibitor and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • Kura Oncology
  • Eiger Biopharmaceuticals

Key Products

  • Tipifarnib
  • Lonafarnib

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/h52gfp

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900